Skip to main content

Morris Gabriel S's Form 4 filing

Immix Biopharma, Inc. (IMMX) · filed Dec 20, 2021

Accession no.
0001493152-21-032035
Filed
Dec 20, 2021, 4:15 PM ET
Trade date
Dec 20, 2021
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $10.0K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Morris Gabriel SCIK 0001889967Director, Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 20, 2021Common StockCConversionAcquired+74,116$0.85+$62,998.674,116Direct
Dec 20, 2021Common StockCConversionAcquired+123,527$0.85+$104,997.95123,527Indirect
Dec 20, 2021Common StockCConversionAcquired+123,176$0.85+$104,699.6246,703Indirect
Dec 20, 2021Common StockPPurchaseAcquired+2,000$5.00+$10,00076,116Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 20, 2021Common stockCConversionDisposed−74,116$0.00–0Direct
Dec 20, 2021Common stockCConversionDisposed−123,527$0.00–0Indirect
Dec 20, 2021Common stockCConversionDisposed−123,176$0.00–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)